DaShenLin Pharmaceutical Group (603233) Revenue Breakdown - Main Composition

17.44
-0.12-0.68%

Market Closed Mar 26 15:00 CST

19.86BMarket Cap17.46P/E (TTM)

DaShenLin Pharmaceutical Group (603233) Revenue Breakdown Overview

By Product

Currency:CNY

2025/H1

Stock NameRevenueRatio

Chinese and western proprietary medicine10.4B76.93%

Non-drug1.78B13.17%

中参药材1.32B9.75%

Total special adjustments19.9M0.15%

By Industry

Currency:CNY

2025/H1

Stock NameRevenueRatio

Retail business11B81.31%

加盟及分销业务2.14B15.80%

Other business390.33M2.89%

By Country/Region

Currency:CNY

2025/H1

Stock NameRevenueRatio

South China8.66B64.06%

东北华北西南及西北地区2.44B18.06%

Central China1.33B9.82%

East China region1.07B7.92%

Total special adjustments19.9M0.15%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Recently, the prospect of a ceasefire negotiation between the US and Iran has been dominating market sentiment. Previously, news that the US Show More

富哥搞钱

Feb 28 17:22

Breaking! The US and Israel jointly bombed Iran. What will be the stock market trend next week?

牛牛課堂

Mar 4 17:09

Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.